Answers are grounded in this paper and cite their sources.
High oral doses of β-alanine are often associated with uncomfortable symptoms of paresthesia, discouraging adherence to supplementation. This study aimed to evaluate the bioavailability, pharmacokinetics, and tolerability of a 400 mg Hydro-Oleo encapsulated β-alanine complex specifically designed to reduce paresthesia. A randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study was conducted in healthy older adults under fasting conditions. The study compared the β-alanine complex with low (400 mg) and high (1200 mg) doses of conventional β-alanine. The β-alanine complex (400 mg) achieved a nearly 4.5-fold and 1.3-fold increase in circulating concentrations compared to 400 mg and 1200 mg of conventional β-alanine, respectively. Importantly, no adverse effects, including paresthesia, were observed despite the higher plasma concentrations. The Hydro-Oleo technology facilitated the controlled release of β-alanine, ensuring enhanced bioavailability and tolerability. This innovative β-alanine complex demonstrates a safe, effective, and sensory-friendly approach to improving β-alanine absorption, particularly for older adults aiming to maintain good health.
No takes yet. Share an insight, caveat, or question.
Gopi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: